References
- Adhikari S.P., Meng S., Wu Y.J., Mao Y.P., Ye R.X., Wang Q.Z., Sun C., Sylvia S., Rozelle S., Raat H. et al.: Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect. Dis. Poverty, 9, 29 (2020)
- Banerjee A., Kulcsar K., Misra V., Frieman M., Mossman K.: Bats and Coronaviruses. Viruses, 11, 41 (2019)
- Baron Y.M.: Could changes in the airborne pollutant particulate matter acting as a viral vector have exerted selective pressure to cause COVID-19 evolution? Med. Hypotheses, 146, 110401–110401 (2021)
- Callaway E.: COVID vaccine excitement builds as Moderna reports third positive result. Nature, 587, 337–338 (2020)
- Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W. et al.: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 395, 514–523 (2020)
- Chen H., Guo J., Wang C., Luo F., Yu X., Zhang W., Li J., Zhao D., Xu D., Gong Q. et al.: Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet, 395, 809–815 (2020)
- Chen X., Yin Y.-H., Zhang M.-Y., Liu J.-Y., Li R., Qu Y.-Q.: Investigating the mechanism of Shu Feng Jie Du capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. Int. J. Med. Sci. 17, 2511–2530 (2020)
- Chen Y., Liu Q., Guo D.: Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 92, 418–423 (2020)
- de Wit E., van Doremalen N., Falzarano D., Munster V.J.: SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016)
- Diaz J.H.: Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J. Travel Med. 27 (2020).
- Du L., He Y., Zhou Y., Liu S., Zheng B.-J., Jiang S.: The spike protein of SARS-CoV – a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009)
- Gil C., Ginex T., Maestro I., Nozal V., Barrado-Gil L., Cuesta-Geijo M., Urquiza J., Ramírez D., Alonso C., Campillo N.E. et al.: COVID-19: Drug Targets and Potential Treatments. J. Med. Chem. 63, 12359–12386 (2020)
- Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H.-J., Tan K.-S., Wang D.-Y., Yan Y.: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Med. Res. 7, 11 (2020)
- Jayaweera M., Perera H., Gunawardana B., Manatunge J.: Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ. Res. 188, 109819–109819 (2020)
- Kannan S., Shaik Syed Ali P., Sheeza A., Hemalatha K.: COVID-19 (Novel Coronavirus 2019) – recent trends. Eur. Rev. Med. Pharmacol. Sci. 24, 2006–2011 (2020)
- Latif A.A., Mukaratirwa S.: Zoonotic origins and animal hosts of coronaviruses causing human disease pandemics: A review. The Onderstepoort J. Vet. Res. 87, e1–e9 (2020)
- Li X., Geng M., Peng Y., Meng L., Lu S.: Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 10, 102–108 (2020)
- Lu C.W., Liu X.F., Jia Z.F.: 2019-nCoV transmission through the ocular surface must not be ignored. Lancet, 395, e39 (2020)
- Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N. et al: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395, 565–574 (2020)
- Mackenzie J.S., Smith D.W.: COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol. Australia, MA20013-MA20013 (2020)
- Miller A., Reandelar M.J., Fasciglione K., Roumenova V., Li Y., Otazu G.H.: Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. medRxiv, 2020. 2003. 2024. 20042937 (2020)
- Peiris J.S.M., Guan Y., Yuen K.Y.: Severe acute respiratory syndrome. Nat. Med. 10, S88–S97 (2004)
- Perlman S., Netland J.: Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7, 439–450 (2009)
- Rauch S., Jasny E., Schmidt K.E., Petsch B.: New Vaccine Technologies to Combat Outbreak Situations. Front. Immun. 9, 1963–1963 (2018)
- Roper R.L., Rehm K.E.: SARS vaccines: where are we? Expert Rev. Vaccines, 8, 887–898 (2009)
- Rothan H.A., Byrareddy S.N.: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 109, 102433 (2020)
- Salvatori G., Luberto L., Maffei M., Aurisicchio L., Roscilli G., Palombo F., Marra E.: SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J. Transl. Med. 18, 222 (2020)
- Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., Bates P.: Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA, 101, 4240–4245 (2004)
- Song Z., Xu Y., Bao L., Zhang L., Yu P., Qu Y., Zhu H., Zhao W., Han Y., Qin C.: From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, 11, 59 (2019)
- Su S., Wong G., Shi W., Liu J., Lai A.C.K., Zhou J., Liu W., Bi Y., Gao G.F.: Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 24, 490–502 (2016)
- https://clinicaltrials.gov/
- Tok TT, G T.: Structures and Functions of Coronavirus Proteins: Molecular Modeling of Viral Nucleoprotein. Int. J. Virol. Infect. Dis., 2(1), 001–007 (2017)
- Tsai Y.-C., Lee C.-L., Yen H.-R., Chang Y.-S., Lin Y.-P., Huang S.-H., Lin C.-W.: Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63. Biomolecules, 10, 366 (2020)
- Velavan T.P., Meyer C.G.: The COVID-19 epidemic. Trop. Med. Int. Health, 25, 278–280 (2020)
- Wan H., Cui J.-A., Yang G.-J.: Risk estimation and prediction of the transmission of coronavirus disease-2019 (COVID-19) in the mainland of China excluding Hubei province. Infect. Dis. Poverty, 9, 116 (2020)
- Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G.: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020)
- Weiss S.R., Leibowitz J.L.: Coronavirus pathogenesis. Adv. Virus Res. 81, 85–164 (2011)
- World Health O.: Coronavirus disease 2019 (COVID-19): situation report, 87. In Geneva: World Health Organization (2020)
- Worldometers.info: Worldometers. In. https://www.worldometers.info/coronavirus/
- Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J. et al.: Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe, 27, 325–328 (2020)
- Yang Y., Peng F., Wang R., Yange M., Guan K., Jiang T., Xu G., Sun J., Chang C.: The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun., 109, 102434 (2020)
- Zhu F.C., Guan X.H., Li Y.H., Huang J.Y., Jiang T., Hou L.H., Li J.X., Yang B.F., Wang L., Wang W.J. et al.: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 396, 479–488 (2020)
- Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R. et al.: A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020)